Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results
Feb 18, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Feb. 18, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2015. For the fourth quarter of 2015, the Company...
Qorvo® to Showcase Expanding Portfolio of RF Solutions at 2016 Mobile World Congress
Feb 18, 2016 13:00 pm UTC| Business
GREENSBORO, N.C. and HILLSBORO, Ore., Feb. 18, 2016 -- Qorvo®, Inc. (NASDAQ:QRVO), a leading provider of core technologies and RF solutions for mobile, infrastructure and defense applications, today announced it will...
Parnell to Report Financial Results for Fiscal Year 2015 on February 24, 2016
Feb 18, 2016 13:00 pm UTC| Business
OVERLAND PARK, Kan., Feb. 18, 2016 -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health...
Atlas Air Worldwide Reports Fourth-Quarter and Full-Year 2015 Earnings
Feb 18, 2016 13:00 pm UTC| Business
4Q15 Adjusted Net Income of $39.4 Million, $1.59 per ShareFull-Year Adjusted Net Income of $125.3 Million, $5.01 per Share4Q15 Reported Net Loss of $37.6 Million, $1.53 per ShareFull-Year Reported Net Income of $7.3...
Feb 18, 2016 13:00 pm UTC| Business
WALTHAM, Mass., Feb. 18, 2016 -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, and...
U.S. Department of Defense Awards Iridium $8.57 Million Task Order for Gateway Modernization
Feb 18, 2016 13:00 pm UTC| Business
MCLEAN, Va., Feb. 18, 2016 -- Iridium Communications Inc. (NASDAQ:IRDM) announced today that it has been awarded a $8.57 million task order, under the Gateway Modernization Efforts contract, from the Defense Information...
Feb 18, 2016 13:00 pm UTC| Business
NEW YORK, Feb. 18, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will...